ReviewFrontiers in oncology2023
Multiple primary lung cancer: Updates of clinical management and genomic features.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Paired Inter-Lesion Invasiveness and Recurrence Risk in Synchronous Multiple Primary Lung Adenocarcinoma: Focus on the IAC-Dominant Subgroup.Journal of clinical medicine · 2026Article
- Article
- Clinico‑pathological profile of oral squamous cell carcinoma: a five‑year analysis of 150 cases at Alexandria University.BMC oral health · 2026Article
- Predicting Overall Survival in Patients With Multiple Primary Lung Cancer: Nomogram Development and Validation Study.JMIR cancer · 2026Article
- CEACAM5 as a biomarker of semi-solid, lepidic lung adenocarcinoma.Translational lung cancer research · 2026Article
- Image-Guided Thermal Ablation of Stage 1 Single and Multiple Primary Lung Carcinoma: Five-Year Outcomes.Medical sciences (Basel, Switzerland) · 2026Article
- A CT-based deep learning approach to differentiate multiple primary lung cancers, metastases, and benign nodules.BMC cancer · 2026Article
- Second Primary Lung Cancer Associated With Family History of Lung Cancer.Cancer medicine · 2025Article
- Comparative microbiome profiling reveals unique signatures in multiple primary lung cancers.Translational cancer research · 2025Article
- Case Report: A Bilateral Synchronous Primary Non-Small Cell Lung Cancer Patient With Two Different EGFR Mutations.Cancer reports (Hoboken, N.J.) · 2025Article
- [Triple synchronous primary lung adenocarcinoma: A diagnostic challenge].Anales del sistema sanitario de Navarra · 2025Article
- Impact of chemoradiotherapy for first primary lung cancer on the prognosis and re-chemoradiotherapy sensitivity of second primary lung cancer.Frontiers in immunology · 2025Article
- Adenocarcinoma and squamous cell carcinoma in the same lobe of the lung with adenocarcinoma metastasis in the lymph nodes: a case report and literature review.Frontiers in oncology · 2025Article
- Super multiple primary lung cancers harbor high-frequency BRAF and low-frequency EGFR mutations in the MAPK pathway.NPJ precision oncology · 2024Article
- Inhalable nanoparticles with enhanced cuproptosis and cGAS-STING activation for synergistic lung metastasis immunotherapy.Acta pharmaceutica Sinica. B · 2024Article
- Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer.Cancer immunology, immunotherapy : CII · 2024Article
- Bilateral synchronous double primary lung cancer: A case report.Clinical case reports · 2024Article
- Long-term prognosis analysis of surgical therapy for bilateral synchronous multiple primary lung cancer: a follow-up of 293 cases.Journal of thoracic disease · 2024Article
- [Recent Advances in Diagnosis and Treatment Strategies for Multiple Primary Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Concurrent Small Cell and Non-Small Cell Lung Cancers: The Diagnostic and Management Challenges of Synchronous Primary Lung Tumors.Kansas journal of medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, multiple primary lung cancer (MPLC) has been increasingly prevalent in clinical practice. However, many details about MPLC have not been completely settled, such as understanding the driving force, clinical management, pathological mechanisms, and genomic architectures of this disease. From the perspective of diagnosis and treatment, distinguishing MPLC from lung cancer intrapulmonary metastasis (IPM) has been a clinical hotpot for years. Besides, compared to patients with single lung lesion, the treatment for MPLC patients is more individualized, and non-operative therapies, such as ablation and stereotactic ablative radiotherapy (SABR), are prevailing. The emergence of next-generation sequencing has fueled a wave of research about the molecular features of MPLC and advanced the NCCN guidelines. In this review, we generalized the latest updates on MPLC from definition, etiology and epidemiology, clinical management, and genomic updates. We summarized the different perspectives and aimed to offer novel insights into the management of MPLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.